title: Impact of the mobilization regimen and the harvesting technique on the granulocyte yield in healthy donors for granulocyte transfusion therapy.
abstract: BACKGROUND
  Granulocyte mobilization and harvesting, the two major phases of granulocyte collection, have not been standardized.
  
  
  METHODS
  The data on 123 granulocyte collections were retrospectively investigated for the effect of the mobilization regimen and the harvesting technique. After a single subcutaneous dose (600 µg) of granulocyte-colony-stimulating factor (G-CSF) with (n = 68) or without (n = 40) 8 mg of orally administered dexamethasone, 108 granulocyte donors underwent granulocyte collections. Moreover, 15 peripheral blood stem cell (PBSC) donors who had received 400 µg/m2 or 10 µg/kg G-CSF for 5 days underwent granulocyte collections on the day after the last PBSC collections (PBSC-GTX donors). Granulocyte harvesting was performed by leukapheresis with (n = 108) or without (n = 15) using high-molecular-weight hydroxyethyl starch (HES).
  
  
  RESULTS
  Granulocyte donors who received mobilization with G-CSF plus dexamethasone produced significantly higher granulocyte yields than those who received G-CSF alone (7.2 × 10(10)  ± 2.0 × 10(10) vs. 5.7 × 10(10)  ± 1.7 × 10(10) , p = 0.006). PBSC-GTX donors produced a remarkably high granulocyte yield (9.7 × 10(10)  ± 2.3 × 10(10) ). The use of HES was associated with better granulocyte collection efficiency (42 ± 7.8% vs. 10 ± 9.1%, p < 0.0001).
  
  
  CONCLUSIONS
  G-CSF plus dexamethasone produces higher granulocyte yields than G-CSF alone. Granulocyte collection from PBSC donors appears to be a rational strategy, since it produces high granulocyte yields when the related patients are at a high risk for infection and reduces difficulties in finding granulocyte donors. HES should be used in apheresis procedures.
authors.affiliation: Department of Transfusion Medicine, the Division of Hematology, Hyogo College of Medicine, Hyogo, Japan.
authors.forename: Junko
authors.initials: J
authors.lastname: Ikemoto
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yoshihara
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Fujioka
authors.forename: Yoshitoshi
authors.initials: Y
authors.lastname: Ohtsuka
authors.forename: Noriko
authors.initials: N
authors.lastname: Fujita
authors.forename: Akira
authors.initials: A
authors.lastname: Kokubunji
authors.forename: Noriaki
authors.initials: N
authors.lastname: Okamoto
authors.forename: Junichiro
authors.initials: J
authors.lastname: Ono
authors.forename: Kyoko
authors.initials: K
authors.lastname: Taniguchi
authors.forename: Katsuji
authors.initials: K
authors.lastname: Kaida
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ikegame
authors.forename: Masaya
authors.initials: M
authors.lastname: Okada
authors.forename: Takakuni
authors.initials: T
authors.lastname: Tanizawa
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Ogawa
authors.forename: Shunro
authors.initials: S
authors.lastname: Kai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000094902:Blood Banking / Q000379:methods*; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006098:Granulocytes / Q000166:cytology*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000008:administration & dosage / Q000009:adverse effects; D007937:Leukapheresis / Q000379:methods*; D008297:Male; D008875:Middle Aged; D010952:Plasma Substitutes / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D016179:Granulocyte Colony-Stimulating Factor; D003907:Dexamethasone